Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 40

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Transitional cell cancer of the renal pelvis and ureter+1

Not recruiting

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Padeliporfin
  • Sponsor:Steba Biotech S.A.

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Neoplasm malignant+2

Not recruiting

Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tyra-300-B01
  • Sponsor:Tyra Biosciences Inc.

Lupus nephritis+1

Not recruiting

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Focal segmental glomerulosclerosis

Not recruiting

Study of BI 764198 for Patients with Focal Segmental Glomerulosclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim International GmbH

Non-Hodgkin's lymphoma+13

Not recruiting

Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tazemetostat
  • Sponsor:Epizyme Inc.

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Congenital cystic kidney disease

Not recruiting

Study on the Effects of Amiloride and Sodium Chloride on Vascular Stiffness in Patients with Polycystic Kidney Disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amiloride
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Thrombotic microangiopathy

Not recruiting

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Methylmalonic acidaemia

Not recruiting

Study on mRNA-3705 for Patients with Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Mrna Encoding Human Methylmalonyl-Coenzyme A Mutase Containing A Polymorphism At Position 671
  • Sponsor:Moderna Therapeutics Inc.

Bladder transitional cell carcinoma

Not recruiting

Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.